Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

@article{Zhu2020ArbidolMI,
  title={Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19},
  author={Zhen Zhu and Zhaohui Lu and Tianmin Xu and Cong Chen and Gang Yang and Tao Zha and Jianchun Lu and Yuan Xue},
  journal={The Journal of Infection},
  year={2020},
  volume={81},
  pages={e21 - e23}
}
Abstract Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases… Expand
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 12 REFERENCES
[Management of corona virus disease-19 (COVID-19): the Zhejiang experience].
  • Kaijin Xu, H. Cai, +14 authors Lanjuan Li
  • Medicine
  • Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • 2020
2019 Novel coronavirus: where we are and what we know
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
...
1
2
...